Skip to main content
Loading

Understanding the biology in both tumor (site of efficacy) and normal (sites of potential dose limiting toxicity), & understanding how to tailor the linker to that biology [Topic TBC]

28 Apr 2026
ADC Linker Design & Conjugation Technologies
Industry Expert
Candida Cristina Quarta, Executive Director - Alexion Pharmaceuticals